Cargando…

Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection

Hepatitis C virus (HCV) infection is a disease that affects millions of people worldwide and has an enormous global public health impact. Chronic HCV is a long-term infection that goes unnoticed until the virus destroys the liver enough to induce liver disease symptoms. The inadequate and poorly tol...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Rowan, Kareem, Roaa, Venkatesan, Nanditha, Botleroo, Rinky A, Ogeyingbo, Opemipo D, Bhandari, Renu, Gyawali, Mallika, Elshaikh, Abeer O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443867/
https://www.ncbi.nlm.nih.gov/pubmed/34540464
http://dx.doi.org/10.7759/cureus.17237
_version_ 1784568381495574528
author Ahmed, Rowan
Kareem, Roaa
Venkatesan, Nanditha
Botleroo, Rinky A
Ogeyingbo, Opemipo D
Bhandari, Renu
Gyawali, Mallika
Elshaikh, Abeer O
author_facet Ahmed, Rowan
Kareem, Roaa
Venkatesan, Nanditha
Botleroo, Rinky A
Ogeyingbo, Opemipo D
Bhandari, Renu
Gyawali, Mallika
Elshaikh, Abeer O
author_sort Ahmed, Rowan
collection PubMed
description Hepatitis C virus (HCV) infection is a disease that affects millions of people worldwide and has an enormous global public health impact. Chronic HCV is a long-term infection that goes unnoticed until the virus destroys the liver enough to induce liver disease symptoms. The inadequate and poorly tolerated treatment contributes to the burden of chronic HCV. Treatments have improved over time - direct-acting antivirals (DAAs) that targeted different hepatitis C virus genomic sites have shown to be more effective and well-tolerated. Patients recover to a greater extent following a treatment regimen based on DAAs. We conducted this literature review to investigate the effectiveness of these medications in treating chronic HCV infection. Relevant articles were identified by searching PubMed and Google scholar databases. Our primary goal was to analyze the efficacy and safety of the DAA, sofosbuvir plus velpatasvir, with or without ribavirin, in cirrhotic or non-cirrhotic, naïve or previously treated, chronic HCV patients. We found that treating patients with sofosbuvir-velpatasvir for 12 weeks was highly effective with fewer adverse events, including those with compensated cirrhosis. The outcomes aided in improving HCV treatment, lowering the disease's burden and fatality rate.
format Online
Article
Text
id pubmed-8443867
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-84438672021-09-17 Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection Ahmed, Rowan Kareem, Roaa Venkatesan, Nanditha Botleroo, Rinky A Ogeyingbo, Opemipo D Bhandari, Renu Gyawali, Mallika Elshaikh, Abeer O Cureus Internal Medicine Hepatitis C virus (HCV) infection is a disease that affects millions of people worldwide and has an enormous global public health impact. Chronic HCV is a long-term infection that goes unnoticed until the virus destroys the liver enough to induce liver disease symptoms. The inadequate and poorly tolerated treatment contributes to the burden of chronic HCV. Treatments have improved over time - direct-acting antivirals (DAAs) that targeted different hepatitis C virus genomic sites have shown to be more effective and well-tolerated. Patients recover to a greater extent following a treatment regimen based on DAAs. We conducted this literature review to investigate the effectiveness of these medications in treating chronic HCV infection. Relevant articles were identified by searching PubMed and Google scholar databases. Our primary goal was to analyze the efficacy and safety of the DAA, sofosbuvir plus velpatasvir, with or without ribavirin, in cirrhotic or non-cirrhotic, naïve or previously treated, chronic HCV patients. We found that treating patients with sofosbuvir-velpatasvir for 12 weeks was highly effective with fewer adverse events, including those with compensated cirrhosis. The outcomes aided in improving HCV treatment, lowering the disease's burden and fatality rate. Cureus 2021-08-16 /pmc/articles/PMC8443867/ /pubmed/34540464 http://dx.doi.org/10.7759/cureus.17237 Text en Copyright © 2021, Ahmed et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Ahmed, Rowan
Kareem, Roaa
Venkatesan, Nanditha
Botleroo, Rinky A
Ogeyingbo, Opemipo D
Bhandari, Renu
Gyawali, Mallika
Elshaikh, Abeer O
Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection
title Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection
title_full Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection
title_fullStr Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection
title_full_unstemmed Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection
title_short Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection
title_sort sofosbuvir/velpatasvir - a promising treatment for chronic hepatitis c virus infection
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8443867/
https://www.ncbi.nlm.nih.gov/pubmed/34540464
http://dx.doi.org/10.7759/cureus.17237
work_keys_str_mv AT ahmedrowan sofosbuvirvelpatasvirapromisingtreatmentforchronichepatitiscvirusinfection
AT kareemroaa sofosbuvirvelpatasvirapromisingtreatmentforchronichepatitiscvirusinfection
AT venkatesannanditha sofosbuvirvelpatasvirapromisingtreatmentforchronichepatitiscvirusinfection
AT botleroorinkya sofosbuvirvelpatasvirapromisingtreatmentforchronichepatitiscvirusinfection
AT ogeyingboopemipod sofosbuvirvelpatasvirapromisingtreatmentforchronichepatitiscvirusinfection
AT bhandarirenu sofosbuvirvelpatasvirapromisingtreatmentforchronichepatitiscvirusinfection
AT gyawalimallika sofosbuvirvelpatasvirapromisingtreatmentforchronichepatitiscvirusinfection
AT elshaikhabeero sofosbuvirvelpatasvirapromisingtreatmentforchronichepatitiscvirusinfection